The dramatic improvement in cash burn and gross margins, combined with multiple pipeline catalysts (PDUFA Sept 2026, Phase 3 AK, Phase 2b acne), suggests a potential inflection point. Monitor for sBCC approval in September and any partnership/licensing announcements that could accelerate profitability.
Price Chart
Executive Summary
Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero cash burn ($70K used in operations). The company has multiple near-term catalysts including a PDUFA date for sBCC in September 2026 and positive Phase 3 AK data, but remains unprofitable with a net loss of $4.8M.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $10.1M, up 17% YoY from $8.6M
- Gross margin expanded to ~80% from ~62% YoY
- Net loss $4.8M ($0.41/share) vs $4.2M ($0.47/share) YoY
- Cash used in operations only $70K, ending cash $6.3M
- PDUFA date for Ameluz sBCC set for September 28, 2026
- Positive Phase 3 AK data on extremities/neck/trunk; Phase 2b acne data with 58% lesion reduction
- Regained Nasdaq compliance on May 6, 2026
Financial Impact
Revenue growth of 17% YoY to $10.1M; gross margin improvement of 18pp to ~80%; operating cash burn near zero ($70K)
Risk Factors
- Still unprofitable with $4.8M net loss; path to sustained profitability uncertain
- Relies on single product platform (Ameluz PDT); regulatory or commercial setbacks would be material
- Convertible notes ($4.7M) and warrant liabilities ($0.6M) add balance sheet risk
- Small market cap ($12M) implies high volatility and limited liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294804 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 8-K | $1.36 | awaiting T+60 | — | $0.8130 (−40.22%) |
Aug 13, 2026 10w ago | 8-K | $1.26 | awaiting T+60 | — | $0.8130 (−35.48%) |
May 14, 2026 23w ago | Press Release | $0.9890 $1.21 | ▲ +22.35% | ▲ +18.76% | $0.8130 (−17.80%) |
May 8, 2026 24w ago | Press Release | $1.11 $1.24 | ▲ +11.71% | ▲ +7.32% | $0.8130 (−26.76%) |
Mar 19, 2026 31w ago | Press Release | $0.8560 $1.00 | ▲ +16.82% | ▲ +2.48% | $0.8130 (−5.02%) |
Feb 26, 2026 34w ago | 8-K | $0.9270 $0.7790 | ▼ −15.97% | ▼ −23.72% | $0.8130 (−12.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers